Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 20:34:19 GMT 2025
by
admin
on
Tue Apr 01 20:34:19 GMT 2025
|
Protein Sub Type | ANTIGEN |
Sequence Origin | Other Species (select) |
Sequence Type | COMPLETE |
Record UNII |
K3L4X0501F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
249207
Created by
admin on Tue Apr 01 20:34:19 GMT 2025 , Edited by admin on Tue Apr 01 20:34:19 GMT 2025
|
||
|
NCI_THESAURUS |
C1663
Created by
admin on Tue Apr 01 20:34:19 GMT 2025 , Edited by admin on Tue Apr 01 20:34:19 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/11/923
Created by
admin on Tue Apr 01 20:34:19 GMT 2025 , Edited by admin on Tue Apr 01 20:34:19 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB177845
Created by
admin on Tue Apr 01 20:34:19 GMT 2025 , Edited by admin on Tue Apr 01 20:34:19 GMT 2025
|
PRIMARY | |||
|
1108208-65-6
Created by
admin on Tue Apr 01 20:34:19 GMT 2025 , Edited by admin on Tue Apr 01 20:34:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107863
Created by
admin on Tue Apr 01 20:34:19 GMT 2025 , Edited by admin on Tue Apr 01 20:34:19 GMT 2025
|
PRIMARY | |||
|
WW-34
Created by
admin on Tue Apr 01 20:34:19 GMT 2025 , Edited by admin on Tue Apr 01 20:34:19 GMT 2025
|
PRIMARY | |||
|
K3L4X0501F
Created by
admin on Tue Apr 01 20:34:19 GMT 2025 , Edited by admin on Tue Apr 01 20:34:19 GMT 2025
|
PRIMARY | |||
|
946156-74-7
Created by
admin on Tue Apr 01 20:34:19 GMT 2025 , Edited by admin on Tue Apr 01 20:34:19 GMT 2025
|
ALTERNATIVE | |||
|
DB05374
Created by
admin on Tue Apr 01 20:34:19 GMT 2025 , Edited by admin on Tue Apr 01 20:34:19 GMT 2025
|
PRIMARY | |||
|
C69076
Created by
admin on Tue Apr 01 20:34:19 GMT 2025 , Edited by admin on Tue Apr 01 20:34:19 GMT 2025
|
PRIMARY | |||
|
100000163538
Created by
admin on Tue Apr 01 20:34:19 GMT 2025 , Edited by admin on Tue Apr 01 20:34:19 GMT 2025
|
PRIMARY |
From | To |
---|---|
1_48 | 1_57 |
1_169 | 1_236 |
1_307 | 1_319 |
1_452 | 1_463 |
1_581 | 1_647 |
1_876 | 1_887 |
1_999 | 1_1066 |
1_1156 | 1_1162 |
1_1293 | 1_1302 |
1_1408 | 1_1475 |
1_1563 | 1_1573 |
1_1705 | 1_1716 |
1_1831 | 1_1898 |
1_1987 | 1_1993 |
1_2122 | 1_2132 |
1_2244 | 1_2311 |
1_2398 | 1_2404 |
1_2542 | 1_2552 |
1_2654 | 1_2721 |
1_2808 | 1_2814 |
1_2946 | 1_2956 |
1_3059 | 1_3126 |
1_3345 | 1_3378 |
Linkage Type | Residue Index | |||||
---|---|---|---|---|---|---|
COORDINATION COMPOUND | 1_2940 | 1_2959 | 1_2968 | 1_3069 | 1_3073 | 1_3100 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ORGANISM->BIOSYNTHETIC PRODUCT |
|
||
|
TARGET->ANTIGEN |
Vaccination with rindopepimut may elicit a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing EGFRvIII.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Structural Modifications
Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
---|---|---|---|---|---|---|
AMINO_ACID_SUBSTITUTION | RESIDUE_SPECIFIC | K |
Amount:
|
RINDOPEPIMUT PEPTIDE MODIFICATION | XE2CRB6S1Q | |
AMINO_ACID_SUBSTITUTION | [1_2940] [1_2959] [1_2968] [1_3069] [1_3073] [1_3100] | SITE_SPECIFIC | UNSPECIFIED SUBSTANCE |
c800a05e
(not in database)
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
Molecular Formula | CHEMICAL |
|